Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
VX-770 for the Treatment of Chronic Bronchitis

This research study will test how well a new drug affects bronchiectasis or chronic bronchitis. The new drug, Ivacaftor (KALYDECO), is a drug that has recently been approved by the U.S. Food and

pulmonary disease
cardiac arrhythmia
diabetes
bronchodilator
vx-770
  • 1 views
  • 10 Jul, 2021
  • 1 location
A Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are <24 months of age at treatment

ivacaftor
sweat test
fibrosis
  • 0 views
  • 28 Jan, 2021
  • 23 locations
Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

Trikafta. Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del

pulmozyme
tezacaftor
elexacaftor
dnase
ivacaftor
  • 55 views
  • 26 Jan, 2021
  • 74 locations
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

The purpose of this pilot study is to explore wither ivacaftor in refractory CRS patients will demonstrate safety and tolerability; restore CFTR-mediated Cl- secretions as measured by EDSPD

rhinosinusitis
ivacaftor
cavities
ct scan
  • 6 views
  • 28 Jun, 2021
  • 1 location
The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor

The study is a Phase 2 Study to establish the safety and efficacy of a drug called Ivacaftor (VX-770) in patients with chronic obstructive pulmonary disease (COPD), chronic bronchitis, and

bronchitis
pulmonary disease
COPD
copd exacerbation
bronchodilator
  • 120 views
  • 21 Aug, 2021
  • 1 location
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations

Based on previous clinical findings, the investigator hypothesize that ivacaftor will have synergistic effects with drugs that facilitate truncated but partially active W1282X CFTR protein

ivacaftor
tezacaftor
cystic fibrosis transmembrane conductance regulator
nonsense mutation
spirometry
  • 5 views
  • 10 May, 2021
  • 1 location
Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi .

The purpose of the study is to investigate whether the correction of CFTR function by Lumacaftor/Ivacaftor in a patient-derived primary nasal cell model is a surrogate biomarker for respiratory

diagnostic procedures
ivacaftor
orkambi
lumacaftor
  • 0 views
  • 24 Jan, 2021
  • 1 location
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination therapy in CF subjects

  • 0 views
  • 23 Sep, 2021
  • 17 locations
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor, tezacaftor and ivacaftor triple combination therapy (Kaftrio

elexacaftor
ivacaftor
tezacaftor
spirometry
fibrosis
  • 52 views
  • 12 Jul, 2021
  • 8 locations
Personalized Theratyping Trial

The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.

cftr modulators
  • 0 views
  • 26 Jan, 2021
  • 1 location